Abstract
Introduction
With current blockbuster brands facing generic competition, Datamonitor
forecasts the antidepressant market to decline at a compound annual growth
rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of
action has huge commercial potential and the most promising candidate to date
is Servier and Novartis' s melatonin agonist and serotonin antagonist Valdoxan
(agomelatine).
Scope of this research
- In-depth analysis of the current and future antidepressant drug class
market across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, generics
and pipeline agents across the seven major markets to 2018.
- Assessment and appreciation of the numerous opportunities and threats
present in the antidepressant market, with analysis of emerging markets trends.
- Case study evaluation of the strategies employed by key players in the
antidepressant drug class market, including Wyeth, Forest, and Lundbeck.
Research and analysis highlights
Japan will remain a key growth market for antidepressant sales, shown through
the launch of Remeron (mirtazapine; Schering Plough), Lexapro (escitalopram;
Lundbeck and Mochida), Cymbalta (duloxetine; Eli Lilly and Shionogi) and
Pristiq (desvenlafaxine; Wyeth).
Eli Lilly' s efforts to gain a broad range of indication approvals for Cymbalta
has been a key differentiator from Effexor (venlafaxine, Wyeth). The approvals
for diabetic peripheral neuropathic pain (US and EU) and fibromyalgia (US
only) will help drive Cymbalta' s uptake through the forecast period, before
the entry of generic duloxetine in 2012.
With its innovative mode of action, strong efficacy and favorable side-effect
profile, Valdoxan (agomelatine; Servier and Novartis) is an exciting new
antidepressant. Assuming US launch in 2012 (EU launch came in 2009),
Datamonitor expects Valdoxan to prosper due to the lack of other truly novel
pipeline products over the 10-year forecast period.
Key reasons to purchase this research
- Quantify the current and future size of the antidepressant drug class
market.
- Assess the impact of recent and anticipated events (patent expiries and
new product launches) on the antidepressant drug class market.
- Understand the country-specific impact of key events in the antidepressant
drug class market during the forecast period 2009 to 2018.
- Delicious Digg it Stumble It!
| 
View Cart
